KLOW (80 mg Blend) Dosage Protocol

KLOW Dosage Chart

KLOW is a multi-peptide blend combining TB-500 (10 mg), BPC-157 (10 mg), KPV (10 mg), and GHK-Cu (50 mg) for a total of 80 mg per vial. TB-500 (synthetic thymosin beta-4) promotes wound healing, angiogenesis, and tissue repair^[1][2]. BPC-157 exhibits regenerative properties with preclinical evidence supporting tendon, ligament, and muscle healing^[3][4]. KPV is an anti-inflammatory tripeptide that modulates NF-κB signaling^[5][6]. GHK-Cu supports collagen synthesis, wound healing, and tissue regeneration^[7][8]. This educational protocol presents a once-daily subcutaneous approach using a practical dilution for clear insulin-syringe measurements.

Research context: For evidence on mechanisms, human and preclinical research, limitations, and safety, read KLOW Peptide: Benefits, Uses, Side Effects, Dosage, and Research.

Dosing & Reconstitution Guide

Educational guide for reconstitution and daily dosing

Standard / Gradual Approach (3 mL = ~26.7 mg/mL Total)

This multi-peptide blend provides synergistic regenerative, anti-inflammatory, and tissue-repair support. The following titration schedule allows gradual introduction of each component.

Frequency: Inject once daily subcutaneously. This schedule uses a 3.0 mL dilution to maintain measurable volumes. For ≤10-unit (≤0.10 mL) administrations during initial weeks, consider 30- or 50-unit insulin syringes for improved readability.

Reconstitution Steps

1. Draw 3.0 mL bacteriostatic water with a sterile syringe.
2. Inject slowly down the vial wall; avoid foaming.
3. Gently swirl/roll until dissolved (do not shake).
4. Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.

Syringe Math Reference

With 3.0 mL reconstitution volume and 80 mg total peptide:

• Total concentration: 26.67 mg/mL (26,667 mcg/mL)
• TB-500: 3.33 mg/mL → 33.3 mcg per unit
• BPC-157: 3.33 mg/mL → 33.3 mcg per unit
• KPV: 3.33 mg/mL → 33.3 mcg per unit
• GHK-Cu: 16.67 mg/mL → 166.7 mcg per unit
• 1 unit (0.01 mL) = 33.3 mcg each of TB-500, BPC-157, KPV + 166.7 mcg GHK-Cu

Protocol Overview

Concise summary of the once-daily regimen.

• Goal: Support tissue repair, reduce inflammation, and promote regeneration through synergistic peptide action^[1][3][5][7].
• Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
• Dose Range: Gradual titration from low to moderate doses based on individual response.
• Reconstitution: 3.0 mL per 80 mg vial (~26.7 mg/mL total) for accurate unit measurements.
• Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.

Dosing Protocol

Suggested daily titration approach.

• Start: 7.5 units daily (0.075 mL) for initial assessment period.
• Increase: Progress to 15 units by Week 3, then 22.5 units by Week 5 as tolerated.
• Maintenance: 15 units daily for extended protocols.
• Frequency: Once per day (subcutaneous).
• Cycle Length: 8–12 weeks; optional extension to 16 weeks.
• Timing: Any consistent time; rotate injection sites.

Storage Instructions

Proper storage preserves peptide quality.

• Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure^[9].
• Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 14–28 days and avoid freeze–thaw.
• Allow vials to reach room temperature before opening to reduce condensation uptake.

Important Notes

Practical considerations for consistency and safety.

• Use new sterile insulin syringes for each injection; dispose in a sharps container.
• Rotate injection sites (abdomen, thighs, upper arms) to reduce local irritation^[10].
• Inject slowly; wait a few seconds before withdrawing the needle.
• Document daily dose and site rotation to maintain consistency.
• This multi-peptide blend may provide broader regenerative support than single-peptide protocols.

How This Works

KLOW combines four peptides with complementary mechanisms of action:

• TB-500 (Thymosin Beta-4): Promotes angiogenesis, cell migration, and tissue repair by regulating actin, a key protein in cell structure^[1]. Preclinical studies demonstrate accelerated wound healing, reduced inflammation, and tissue regeneration^[2].
• BPC-157: A gastric pentadecapeptide that supports tendon, ligament, and muscle healing through enhanced angiogenesis and growth factor modulation^[3]. Animal studies show favorable tissue repair outcomes^[4].
• KPV: A C-terminal tripeptide fragment of α-MSH with potent anti-inflammatory properties. It inhibits NF-κB signaling and reduces pro-inflammatory cytokines without melanotropic effects^[5][6].
• GHK-Cu: A naturally occurring copper peptide that stimulates collagen and elastin synthesis, promotes wound healing, and modulates gene expression related to tissue remodeling^[7][8].

Potential Benefits & Side Effects

Observations from preclinical and early-stage research.

Potential Benefits

• Accelerated tissue repair and wound healing through multiple complementary pathways^[1][3].
• Reduced inflammation via NF-κB inhibition and cytokine modulation^[5][7].
• Enhanced collagen synthesis and connective tissue support^[8].
• Promotion of angiogenesis and improved blood flow to healing tissues^[2].
• Potential support for musculoskeletal recovery and joint health^[3].

Possible Side Effects

• Mild injection-site reactions (redness, irritation) may occur with subcutaneous administration.
• Occasional lightheadedness reported with some peptides due to vasodilatory effects.
• Limited human clinical data; most safety observations derive from preclinical studies^[4].

Lifestyle Factors

Complementary strategies for best outcomes.

• Pair with a balanced, protein-forward diet tailored to support tissue repair and recovery.
• Combine resistance training and mobility work to reinforce musculoskeletal adaptations.
• Prioritize sleep and stress management to optimize the body’s natural regenerative processes.
• Stay well-hydrated to support peptide absorption and overall metabolic function.

Injection Technique

General subcutaneous guidance from clinical best-practice resources^[10][11].

• Clean the vial stopper and skin with alcohol; allow to dry completely.
• Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue^[10].
• Do not aspirate for subcutaneous injections; inject slowly and steadily^[11].
• Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy^[12].
• Apply gentle pressure after withdrawal; do not massage the injection site.

Important Note

This content is for educational purposes only and is not medical advice.

References

• 
  PubMed
  — Thymosin beta 4 accelerates wound healing (Philp et al., 1999)
  View Source
• 
  PubMed
  — Thymosin β4 promotes dermal healing in preclinical models and clinical trials
  View Source
• 
  PMC
  — Emerging use of BPC-157 in orthopaedic sports medicine: systematic review
  View Source
• 
  PMC
  — Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs
  View Source
• 
  PMC
  — PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
  View Source
• 
  PMC
  — Orally targeted delivery of tripeptide KPV via HA-functionalized nanoparticles alleviates ulcerative colitis
  View Source
• 
  PMC
  — Regenerative and protective actions of the GHK-Cu peptide in light of new gene data
  View Source
• 
  PMC
  — GHK peptide as a natural modulator of multiple cellular pathways in skin regeneration
  View Source
• 
  Sigma-Aldrich
  — Handling and storage guidelines for peptides and proteins
  View Source
• 
  CDC
  — Vaccine administration: subcutaneous injection technique guidelines
  View Source
• 
  CDC
  — Vaccine administration best practices (aspiration not recommended for SC injections)
  View Source
• 
  NCBI Bookshelf
  — Chapter 18: Administration of parenteral medications (injection technique)
  View Source
• 
  PubMed
  — Thymosin β4: a multi-functional regenerative peptide (basic properties and clinical applications)
  View Source
• 
  PMC
  — The potential of GHK as an anti-aging peptide
  View Source